Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities.
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of several malignancies; however, their efficacy in platinum-resistant ovarian cancer (PROC) remains limited. The immunosuppressive tumor microenvironment (TME) in ovarian cancer constitutes a major barrier to effective antitumor immunity, pro...